Prof Ritchie is currently Professor of the Psychiatry of Ageing at the University of Edinburgh having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014.
Craig is a leading authority on Clinical Trials in Dementia and has been senior investigator on over 30 drug trials of both disease modifying and symptomatic agents for that condition. This emerged from his ongoing clinical leadership of the MPAC (Metal Protein Attenuating Compound) pipeline for Prana Biotechnology dating back to 1998 when he worked as a Senior Visiting Research Fellow at the Mental Health Research Institute in Victoria, Australia. Craig has sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organisations with an in interest in developing drugs and trials infrastructure for Alzheimer’s disease.
Craig has published extensively on the topics of dementia and delirium. He is also one of the leading editors in the Cochrane Collaboration’s Dementia Group with a particular specialism in Diagnostic Test Accuracy reviews and is Assistant Editor for the journal International Psychogeriatrics.
Craig leads the Alzheimer Society-funded PREVENT project; a major initiative nationally which will identify mid-life risks for later life dementia and characterise early changes of neurodegenerative disease through imaging, genetic, cognitive and biological tests. PREVENT is a core cohort of the MRC Dementias Platform.
Craig also leads the EPAD (European Prevention of Alzheimer’s Dementia) Consortium, which is a 5-year project to establish a pan-European network of Trial Delivery Centres. The EPAD project is part of a global effort in the fight against Alzheimer’s disease and is a major European initiative to create a novel environment for testing numerous interventions targeted at the prevention of Alzheimer’s dementia.
Ritchie K, Carrière I, Berr C, Amieva H, Dartigues JF, Ancelin ML and Ritchie CW. The clinical picture of Alzheimer’s disease in the decade before diagnosis: clinical and biomarker trajectories. J Clin Psych /2016//2016 Mar;77(3):e305-11
Ritchie CW, Molinuevo JL, Satlin A, Van Der Geyten, Lovestone S, Truyen L. The European Prevention of Alzheimer’s Dementia (EPAD) Consortium: A platform to enable the secondary prevention of AD through improved Proof of Concept Trials. Lancet Psychiatry 2016 Feb;3(2):179-86
Gault LM, Ritchie CW, Robieson WZ, Pritchett Y, Othman AA, Cunningham MR, Lenz RA. A phase 2 randomized trial of the agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. (In Press) Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, 2014 14(1):39-47
Ritchie C, Smailagic, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, and McShane R. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014 Jun 10;(6)
Noel-Storr AH, McCleery J, Richard E, Ritchie C, Flicker L, Cullum S, & McShane R. Reporting standards for studies of diagnostic test accuracy in AD and dementia: The STARDdem Initiative Neurology. 2014 Jul 22;83(4):364-73.
Innovative Medicines Initiative: EPAD (European Prevention of Alzheimer’s Dementia) – 2015-2020, £50,000,000
Alzheimer’s Society. PREVENT (identifying mid-life risks for later life dementia and characterise early changes of neurodegenerative disease – 2014-open, £615,000
Janssen R&D: CHARIOT PRO: The Cognitive Health in Ageing Register: Investigational,Observational, and Trial studies in dementia research (CHARIOT):Prospective Readiness cOhort Study (PRO) (Edinburgh) 2016-2020, £6,800,000
Innovative Medicines Initiative: AMYPAD (Amyloid Imaging to Prevent Alzheimer’s Dementia) 2016-2021,€27,329,288.